Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SUPN 
Supernus Pharmaceuticals Inc (SUPN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: SUPN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 12.9% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.77B USD | Price to earnings Ratio 24 | 1Y Target Price 38.8 |
Price to earnings Ratio 24 | 1Y Target Price 38.8 | ||
Volume (30-day avg) 767172 | Beta 0.84 | 52 Weeks Range 25.53 - 40.28 | Updated Date 04/1/2025 |
52 Weeks Range 25.53 - 40.28 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.16% | Operating Margin (TTM) 11.23% |
Management Effectiveness
Return on Assets (TTM) 2.9% | Return on Equity (TTM) 7.55% |
Valuation
Trailing PE 24 | Forward PE 20.16 | Enterprise Value 1408862816 | Price to Sales(TTM) 2.67 |
Enterprise Value 1408862816 | Price to Sales(TTM) 2.67 | ||
Enterprise Value to Revenue 2.13 | Enterprise Value to EBITDA 7.9 | Shares Outstanding 55814500 | Shares Floating 48489960 |
Shares Outstanding 55814500 | Shares Floating 48489960 | ||
Percent Insiders 5.2 | Percent Institutions 110.9 |
Analyst Ratings
Rating 4.2 | Target Price 42.8 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Supernus Pharmaceuticals Inc
Company Overview
History and Background
Supernus Pharmaceuticals, Inc. was founded in 2005. The company focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Core Business Areas
- CNS Pharmaceuticals: Develops and commercializes pharmaceutical products focused on treating CNS disorders, including ADHD, epilepsy, migraine, and Parkinson's disease.
Leadership and Structure
The leadership team includes Jack Khattar (President and CEO). The organizational structure is typical of a pharmaceutical company, with departments for research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Product Name 1: Oxtellar XR: An extended-release formulation of oxcarbazepine for the treatment of epilepsy. Competitors: Trileptal (Novartis). Market share data is not publicly available, but Oxtellar XR is a significant contributor to Supernus revenue.
- Product Name 2: Trokendi XR: An extended-release topiramate formulation for the treatment of epilepsy and migraine. Competitors: Topamax (Janssen). Similar to Oxtellar, market share data is limited, but Trokendi XR is a key revenue driver.
- Product Name 3: Qelbree (viloxazine extended-release capsules): Non-stimulant for the treatment of ADHD in pediatric and adult patients. Competitors: Strattera (Eli Lilly), Intuniv (Takeda). Supernus' key future growth driver.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant investment in research and development. The CNS market is growing due to an aging population and increased awareness of mental health disorders.
Positioning
Supernus is a specialty pharmaceutical company focused on CNS disorders, giving them a focused approach. Their competitive advantage lies in their extended-release formulations and novel therapies.
Total Addressable Market (TAM)
The global CNS therapeutics market is estimated to be worth hundreds of billions of dollars. Supernus is positioned to capture a portion of this TAM through its existing and pipeline products.
Upturn SWOT Analysis
Strengths
- Proprietary extended-release technology
- Focus on CNS disorders
- Established commercial infrastructure
- Diversified product portfolio addressing multiple neurological conditions.
Weaknesses
- Reliance on a limited number of key products
- Exposure to generic competition
- Limited pipeline compared to larger pharmaceutical companies
- Potential for clinical trial failures.
Opportunities
- Expansion into new CNS indications
- Acquisition of complementary products or companies
- Partnerships with larger pharmaceutical companies
- Geographic expansion
Threats
- Generic erosion of key products
- Increased competition from new therapies
- Regulatory hurdles
- Pricing pressures
Competitors and Market Share
Key Competitors
- LLY
- TAK
- JNJ
- NVS
Competitive Landscape
Supernus is a smaller player compared to major pharmaceutical companies like Lilly, Takeda, Johnson & Johnson and Novartis, but it competes effectively in its niche areas of CNS disorders. Its extended-release technologies give it a competitive advantage.
Major Acquisitions
Bicara Therapeutics
- Year: 2024
- Acquisition Price (USD millions): 0.2
- Strategic Rationale: Supernus acquired all outstanding shares of Bicara Therapeutics. Supernus intends to evaluate BCAR269 and several other preclinical assets in autoimmune diseases. The value of the transaction could reach up to $200 million, pending future clinical and regulatory milestones and commercial revenues.
Growth Trajectory and Initiatives
Historical Growth: Supernus has grown through product launches and acquisitions.
Future Projections: Analyst projections vary but generally anticipate revenue growth driven by Qelbree and other products in development.
Recent Initiatives: Recent initiatives include the commercial launch of new products and continued investment in R&D.
Summary
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on CNS disorders. While they have a specialized approach and proprietary technologies, they face competition from larger companies and generic erosion. Their success relies heavily on the continued growth of Qelbree and effective management of pipeline products. Overall, the company's financial well-being will improve, given its current and recent acquisitions.
Similar Companies
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
NVS
Novartis AG ADR
NVS
Novartis AG ADR
RDHL
Redhill Biopharma Ltd
RDHL
Redhill Biopharma Ltd
TAK
Takeda Pharmaceutical Co Ltd ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Analyst Reports, Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Supernus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2012-05-01 | Founder, President, CEO, Secretary & Director Mr. Jack A. Khattar M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 674 | Website https://www.supernus.com |
Full time employees 674 | Website https://www.supernus.com | ||
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.